Pegylated interferon alpha‐2a showed no clear difference in treatment discontinuation compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in adverse events compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in death compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in relapse(recurrence after stopping) compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a may leads to higher end‐of‐treatment response compared with standard interferon (low certainty).
Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).
Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).
Interferon‐α plus bevacizumab showed no clear difference in 1‐year mortality median compared with standard targeted therapies (low certainty).
The review found no eligible studies for this question.
Interferon‐α plus bevacizumab showed no clear difference in adverse events (grade ≥ 3) compared with standard targeted therapies (low certainty).
Interferon‐α combined with targeted therapies may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapy (low certainty).
Interferon‐α combined with targeted therapies showed no clear difference in 1‐year mortality compared with standard targeted therapy (moderate certainty).
The review found no eligible studies for this question.